NA - Companion diagnostic target · neurodegeneration · -
Composite 0.512
Price $0.50
Evidence For 0
Evidence Against 0
A specific threshold represents the point at which amyloid-driven tau pathology has been reduced below the threshold required to sustain neurodegeneration. However, the threshold is operationally undefined—the <0.15 pg/mL value lacks prospective validation and is likely derived from cross-sectional amyloid status cutoffs, not treatment cessation studies. The proposed pragmatic trial to validate this threshold has never been conducted and carries significant ethical and investment risk.
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.45
Evidence
0.42
Novelty
0.55
Feasibility
0.40
Impact
0.75
Druggability
0.70
Safety
0.40
Competition
0.60
Data
0.50
Reproducible
0.35
KG Connect
0.50
Score Breakdown
Dimension
CSF p-tau217 Threshold of <0.1
Mechanistic
0.450
Evidence
0.420
Novelty
0.550
Feasibility
0.400
Impact
0.750
Druggability
0.700
Safety
0.400
Competition
0.600
Data
0.500
Reproducible
0.350
KG Connect
0.500
Evidence
CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clini